Mirum Pharmaceuticals, Inc.: net inventory
Net inventory for Mirum Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Mirum Pharmaceuticals, Inc. financial histories
What this measure means
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
Exact concept: us-gaap:InventoryNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 24,887,000 | USD | 2026-02-25 | 10-K · 0001759425-26-000013 |
| At date | 2024-12-31 | 22,403,000 | USD | 2026-02-25 | 10-K · 0001759425-26-000013 |
| At date | 2023-12-31 | 22,312,000 | USD | 2025-02-26 | 10-K · 0001759425-25-000014 |
| At date | 2022-12-31 | 5,565,000 | USD | 2024-03-15 | 10-K · 0000950170-24-032289 |
| At date | 2021-12-31 | 1,513,000 | USD | 2023-03-08 | 10-K · 0000950170-23-006715 |
| At date | 2020-12-31 | 0 | USD | 2022-03-09 | 10-K · 0000950170-22-003229 |
Related financial histories
- Mirum Pharmaceuticals, Inc.: total assets
- Mirum Pharmaceuticals, Inc.: total liabilities
- Mirum Pharmaceuticals, Inc.: stockholders equity
- Mirum Pharmaceuticals, Inc.: cash and cash equivalents
- Mirum Pharmaceuticals, Inc.: net income or loss
- Mirum Pharmaceuticals, Inc.: operating cash flow
- Mirum Pharmaceuticals, Inc.: capital expenditure payments
- Mirum Pharmaceuticals, Inc.: contract revenue excluding tax
- Mirum Pharmaceuticals, Inc.: financing cash flow
- Mirum Pharmaceuticals, Inc.: investing cash flow
- Mirum Pharmaceuticals, Inc.: retained earnings or deficit
- Mirum Pharmaceuticals, Inc.: basic weighted-average shares
- Mirum Pharmaceuticals, Inc.: diluted weighted-average shares
- Mirum Pharmaceuticals, Inc.: basic earnings per share
- Mirum Pharmaceuticals, Inc.: diluted earnings per share
- Mirum Pharmaceuticals, Inc.: income tax expense or benefit
- Mirum Pharmaceuticals, Inc.: net property, plant and equipment
- Mirum Pharmaceuticals, Inc.: share-based compensation expense
- Mirum Pharmaceuticals, Inc.: operating income or loss
- Mirum Pharmaceuticals, Inc.: current assets
- Mirum Pharmaceuticals, Inc.: current liabilities
- Mirum Pharmaceuticals, Inc.: current accounts payable
- Mirum Pharmaceuticals, Inc.: net finite-lived intangible assets
- Mirum Pharmaceuticals, Inc.: net current accounts receivable
- Mirum Pharmaceuticals, Inc.: operating expenses
- Mirum Pharmaceuticals, Inc.: selling, general and administrative expense
Inspect the source
- Entity
- Mirum Pharmaceuticals, Inc. / CIK 0001759425
- Captured
- 2026-09-21T17:29:38.934Z
- SEC response SHA-256
59bc8f37f77ef3a1713f2e760e85eb8f6c60e92c1e3812c5856da34901351ce8
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001759425.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))